Nautilus Biotechnology (NAUT) - Forward P/E Multiple
Nautilus Biotechnology (NAUT) faces challenges in the commercialization of proteomics and a shortage of funds prior to reaching break-even. The company's expected P/E ratio on the GURU.Markets system summary chart reflects market expectations, where 0.00 determines this parameter level. Equipment delivery requires precision electronics packaging, while the business's future pricing power depends on the technology's efficiency compared to mass spectrometry.
Analytical breakdowns and data insights for company Nautilus Biotechnology Inc (NAUT)
- current price and projected stock value:
- market capitalization indicators:
- book capitalization information:
- debt and liquidity details:
Debt to Equity Nautilus Biotechnology|NAUT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Nautilus Biotechnology|NAUT - Aggregate Debt Obligations|Debts to Book Capitalization Nautilus Biotechnology, Inc.|NAUT - Company Long-Term Debt|Company Short-Term Debts Nautilus Biotechnology|Quick Liquidity nautilus.bio
- company profitability and valuation multiples indicators:
NAUT - Company Net Income|Future Profit Nautilus Biotechnology|NAUT - Market Price to Net Income Ratio|Forward P/E Multiple Nautilus Biotechnology|NAUT - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Nautilus Biotechnology, Inc.|NAUT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Nautilus Biotechnology|NAUT - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months nautilus.bio|NAUT - Earnings per share growth this year|Net earnings per share growth forecast for next year Nautilus Biotechnology
- issuer revenue and sales details:
Fundamental valuation:Nautilus Bio
Cost optimization at Nautilus Biotechnology (NAUT) through the outsourcing of materials production and cloud-based data analysis directly impacts the business's future margins. By analyzing the company's forward P/E ratio, an investor can see the relationship between current market value and expected earnings, allowing for an objective assessment of the asset's overbought status and the avoidance of excessive risks when constructing a portfolio.
Competing companies
Projected Price to Earnings TEM (Tempus Labs)|Market Cap to Future Earnings Ratio QGEN|Forward P/E Multiple IONS (Ionis Pharma)|Market Cap to Projected Earnings Repligen Inc. (RGEN)|RNA - Future Price to Earnings|CRSP: Future Price to Earnings|WGS (GeneDx) - Projected Price to Earnings|Ultragenyx Pharmaceutical Inc. (RARE) - Forward P/E Multiple|Future Price to Earnings Beam Therapeutics Corp|Sarepta Corp (SRPT) - Market Cap to Projected Earnings|Projected Price to Earnings TWST (Twist Bioscience)|TXG (10xgenomics.com) - Future Price to Earnings Multiple|Forward P/E Multiple NTLA (Intellia Therapeutics, Inc.)|Stoke Therapeutics Inc - Future Price to Earnings|BioLife Corp - Forward P/E Multiple|Market Cap to Projected Earnings Wave Pharma WVE|Maze Therapeutics Inc (MAZE) - Future Price to Earnings|Projected Price to Earnings Ratio sionnatx.com (SION)|Projected Price to Earnings PRME|TSHA (Taysha Gene Therapies Inc) - Market Cap to Future Earnings Ratio|Forward P/E Multiple QURE|MGTX - Projected Price to Earnings Ratio|Forward P/E Multiple RGNX (REGENXBIO Inc.)|SLDB - Projected Price to Earnings|Ocugen - Forward P/E Multiple|Future Price to Earnings Multiple PACB (Pacific Biosciences of California, Inc.)|Benitec (BNTC) - Future Price to Earnings|Price to Future Earnings Ratio DSGN|Future Price to Earnings Rocket Pharmaceuticals|Projected Price to Earnings Ratio 4dmoleculartherapeutics.com FDMT|Future Price to Earnings Lexeo Therapeutics (LXEO)|Future Price to Earnings KRRO (korrobio.com)|Future Price to Earnings Editas EDIT|Silence Therapeutics Corp (SLN) - Projected Price to Earnings Ratio|ProQR Therapeutics NV - Forward P/E Multiple|Forward Price to Earnings Multiple Codexis, Inc. (CDXS)|SGMO (Sangamo Therapeutics, Inc.) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi Inc. (MGX)|Future Price to Earnings Precision BioSciences, Inc.|Price to Future Earnings Ratio GBIO (Generation Bio Corp)|Forward P/E Multiple BOLD|Forward P/E Multiple exicuretx.com (XCUR)|Imunon - Projected Price to Earnings|Forward P/E Multiple Phio Pharmaceuticals Corp PHIO|MBIO: Projected Price to Earnings|TransCode Therapeutics - Market Cap to Future Earnings Ratio|BNGO: Forward P/E Multiple|Price to Future Earnings Ratio APDN|Future Price to Earnings bluebird bio|Price to Future Earnings Ratio IPA (ImmunoPrecise)|Forward P/E Multiple OMGA|Forward P/E Multiple Singular Genomics Corp (OMIC)|Future Price to Earnings Regulus Therapeutics RGLS|SYRS: Price to Future Earnings Ratio|Telesis Bio - Forward P/E Multiple|TCON - Forward P/E Multiple|UBX (Unity Bio) - Projected Price to Earnings
